Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects With EphA3-Expressing Hematologic Malignancies

NCT01211691 is registered in ClinicalTrials.gov with Humanigen, Inc. as lead sponsor.

NCT NCT01211691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01211691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects With EphA3-Expressing Hematologic Malignancies
Lead sponsor
Humanigen, Inc.
Phase
Phase 1/2
Overall status
Suspended
Start date
September 30, 2010
Completion date
December 31, 2016
Enrollment
120 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome (mds), myelofibrosis (mf)